About Protein arginine N-methyltransferase 1
Protein arginine N-methyltransferase 1 (PRMT1) is a protein
from Homo sapiens identified by UniProt accession
Q99873, 371 residues long.
MolForge cross-references it against 0 known binders and
242 disease associations.
Target properties
| Protein name | Protein arginine N-methyltransferase 1 |
| UniProt accession | Q99873 |
| Gene | PRMT1 |
| Organism | Homo sapiens |
| Length | 371 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (242)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.46
- COVID-19 · score 0.37
- breast adenocarcinoma · score 0.27
- endometrial cancer · score 0.25
- gastric adenocarcinoma · score 0.24
- body height · score 0.24
- ovarian cancer · score 0.23
- prostate adenocarcinoma · score 0.13
- neoplasm · score 0.11
- hepatocellular carcinoma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99873-F1 | alphafold | PREDICTED | 88.34 | — |
Amino-acid sequence (371 residues)
MAAAEAANCI MENFVATLAN GMSLQPPLEE VSCGQAESSE KPNAEDMTSK DYYFDSYAHF GIHEEMLKDE VRTLTYRNSM FHNRHLFKDK VVLDVGSGTG ILCMFAAKAG ARKVIGIECS SISDYAVKIV KANKLDHVVT IIKGKVEEVE LPVEKVDIII SEWMGYCLFY ESMLNTVLYA RDKWLAPDGL IFPDRATLYV TAIEDRQYKD YKIHWWENVY GFDMSCIKDV AIKEPLVDVV DPKQLVTNAC LIKEVDIYTV KVEDLTFTSP FCLQVKRNDY VHALVAYFNI EFTRCHKRTG FSTSPESPYT HWKQTVFYME DYLTVKTGEE IFGTIGMRPN AKNNRDLDFT IDLDFKGQLC ELSCSTDYRM R
Explore Protein arginine N-methyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets